-
公开(公告)号：US20230241235A1
公开(公告)日：2023-08-03
申请号：US18166774
申请日：2023-02-09
Applicant: Pfizer Inc.
Inventor： Andrea Therese HOOPER , Kimberly Ann MARQUETTE , Chakrapani SUBRAMANYAM , Hans-Peter GERBER , Chad Michael MAY
CPC classification number: A61K47/6811 , A61K47/6843 , A61P35/00 , A61K38/08 , C07K16/18 , A61K47/6803 , C07K2317/21 , C07K2317/52 , C07K2317/565 , C07K2317/33 , C07K2317/92
Abstract: The present invention provides antibodies and antibody-drug conjugates that bind to the extra domain B splice variant of fibronectin 1 and methods for preparing and using the same.
-
公开(公告)号：US20160271270A1
公开(公告)日：2016-09-22
申请号：US15070549
申请日：2016-03-15
Applicant: Pfizer Inc.
Inventor： Andreas MADERNA , Chakrapani SUBRAMANYAM , Lawrence N. TUMEY , Zecheng CHEN , Jeffrey M. CASAVANT
IPC: A61K47/48 , C07F9/6561 , C07K16/32 , C07K5/09 , C07B59/00 , C07K16/28 , C07D519/00 , C07K5/062
CPC classification number: C07K16/32 , A61K47/65 , A61K47/6803 , A61K47/6807 , A61K47/6849 , A61K47/6863 , A61K47/6865 , A61K47/6869 , A61K47/6871 , C07B59/002 , C07B2200/05 , C07D495/04 , C07D519/00 , C07F9/6561 , C07K5/06052 , C07K5/0815 , C07K16/2803 , C07K16/2866
Abstract: The present invention is directed to novel bifunctional CTI-CTI and CBI-CTI dimers of the formula: F1-L1-T-L2-F2 where F1, L1, T, L2 and F2 are as defined herein, useful for the treatment for proliferative diseases, where the inventive dimers can function as stand-alone drugs, payloads in antibody-drug-conjugates (ADCs), and linker-payload compounds useful in connection with the production or administration of such ADCs; and to compositions including the aforementioned dimers, linker-payloads and ADCs, and methods for using these dimers, linker-payloads and ADCs, to treat pathological conditions including cancer.
Abstract translation: 其中F1，L1，T，L2和F2如本文所定义，可用于治疗增殖性疾病，其中本发明的二聚体可用作独立药物，抗体 - 药物共轭物（ADC）中的有效载荷和接头有效载体 可用于生产或管理此类ADC的化合物; 以及包含上述二聚体，连接物有效载体和ADC的组合物，以及使用这些二聚体，连接体有效载体和ADC的方法来治疗包括癌症在内的病理状况。
-
公开(公告)号：US20240181071A1
公开(公告)日：2024-06-06
申请号：US18492055
申请日：2023-10-23
Applicant: Pfizer Inc.
Inventor： Andrea Therese HOOPER , Kimberly Ann MARQUETTE , Chakrapani SUBRAMANYAM , Hans-Peter GERBER , Chad Michael MAY
CPC classification number: A61K47/6803 , A61K47/6843 , A61P35/00 , C07K16/18 , A61K38/08 , A61K47/6811
Abstract: The present invention provides antibodies and antibody-drug conjugates that bind to the extra domain B splice variant of fibronectin 1 and methods for preparing and using the same.
-
公开(公告)号：US20210061923A1
公开(公告)日：2021-03-04
申请号：US17091097
申请日：2020-11-06
Applicant: PFIZER INC.
Inventor： Andreas MADERNA , Chakrapani SUBRAMANYAM , Lawrence N. TUMEY , Zecheng CHEN , Jeffrey M. CASAVANT
IPC: C07K16/32 , C07D519/00 , C07F9/6561 , C07K5/062 , C07K5/09 , C07B59/00 , C07K16/28 , C07D495/04 , A61K47/68 , A61K47/65
Abstract: The present invention is directed to novel bifunctional CTI-CTI and CBI-CTI dimers of the formula: F1-L1-T-L2-F2 where F1, L1, T, L2 and F2 are as defined herein, useful for the treatment for proliferative diseases, where the inventive dimers can function as stand-alone drugs, payloads in antibody-drug-conjugates (ADCs), and linker-payload compounds useful in connection with the production or administration of such ADCs; and to compositions including the aforementioned dimers, linker-payloads and ADCs, and methods for using these dimers, linker-payloads and ADCs, to treat pathological conditions including cancer.
-
公开(公告)号：US20180339060A1
公开(公告)日：2018-11-29
申请号：US16053344
申请日：2018-08-02
Applicant: PFIZER INC.
Inventor： Andreas MADERNA , Matthew David DOROSKI , Zecheng CHEN , Hud Lawrence RISLEY , Jeffrey Michael CASAVANT , Christopher John O'DONNELL , Alexander M. PORTE , Chakrapani SUBRAMANYAM
IPC: A61K47/68 , C07K9/00 , C07K5/06 , C07H17/02 , C07F9/6561 , C07D487/04 , C07D417/14 , C07D409/14 , C07D405/14 , C07D401/14 , A61K38/06 , A61K38/05 , A61K31/7056 , A61K31/675 , A61K31/454 , A61K31/4439 , A61K31/433 , A61K31/407 , A61K31/404 , C07K5/08
CPC classification number: A61K47/6851 , A61K31/404 , A61K31/407 , A61K31/433 , A61K31/4439 , A61K31/454 , A61K31/675 , A61K31/7056 , A61K38/05 , A61K38/06 , A61K47/6803 , A61K47/6807 , A61K47/6811 , C07D401/14 , C07D405/14 , C07D409/14 , C07D417/14 , C07D487/04 , C07F9/6561 , C07H17/02 , C07K5/06 , C07K5/08 , C07K9/003
Abstract: Cytotoxic dimers comprising CBI-based and/or CPI-based sub-units, antibody drug conjugates comprising such dimers, and to methods for using the same to treat cancer and other conditions.
-
Patent Agency Ranking
公开(公告)号：US20240261423A1
公开(公告)日：2024-08-08
申请号：US18528539
申请日：2023-12-04
Applicant: Pfizer Inc.
Inventor： Andrea Therese HOOPER , Kimberly Ann MARQUETTE , Chakrapani SUBRAMANYAM , Hans-Peter GERBER , Chad Michael MAY
CPC classification number: A61K47/6803 , A61K47/6843 , A61P35/00 , C07K16/18 , A61K38/08 , A61K47/6811 , C07K2317/21 , C07K2317/33 , C07K2317/52 , C07K2317/565 , C07K2317/92
Abstract: The present invention provides antibodies and antibody-drug conjugates that bind to the extra domain B splice variant of fibronectin 1 and methods for preparing and using the same.
-
7.发明申请公开(公告)号：US20170014523A1
公开(公告)日：2017-01-19
申请号：US15280563
申请日：2016-09-29
Applicant: PFIZER INC.
Inventor： Chakrapani SUBRAMANYAM , Frank Erich KOEHN , Kenneth John DIRICO , Alessandra S. EUSTAQUIO , Michael Eric GREEN , Haiyin HE , Min HE , Christopher John O'DONNELL , Sujiet PUTHENVEETIL , Anokha RATNAYAKE , Jesse Alexander TESKE , Hui Yu YANG
IPC: A61K47/48 , A61K31/453 , A61K31/4025 , A61K31/351 , A61K31/501 , A61K31/35 , A61K31/496
CPC classification number: A61K47/6855 , A61K31/35 , A61K31/351 , A61K31/397 , A61K31/4025 , A61K31/453 , A61K31/496 , A61K31/501 , A61K45/06 , A61K47/6803 , A61K47/6869 , A61K47/6889 , C07D309/10 , C07D309/14 , C07D405/12 , C07D405/14 , C07D493/10 , C07D493/20
Abstract: The present invention is directed to novel cytotoxic spliceostatin analogs and derivatives, to antibody drug conjugates thereof, and to methods for using the same to treat medical conditions including cancer.
Abstract translation: 本发明涉及新颖的细胞毒素剪接抑制物类似物及其衍生物，其抗体药物偶联物及其用于治疗包括癌症在内的医学病症的方法。
-
公开(公告)号：US20160022626A1
公开(公告)日：2016-01-28
申请号：US14818455
申请日：2015-08-05
Applicant: PFIZER INC.
Inventor： Chakrapani SUBRAMANYAM , Frank Erich Koehn , Kenneth John Dirico , Alessandra S. Eustaquio , Michael Eric Green , Haiyin He , Min He , Christopher John O'Donnell , Sujiet Puthenveetil , Anokha Ratnayake , Jesse Alexander Teske , Hui Yu Yang
IPC: A61K31/351 , A61K47/48 , A61K31/496 , A61K31/501 , A61K31/453 , A61K31/397
CPC classification number: A61K47/6855 , A61K31/35 , A61K31/351 , A61K31/397 , A61K31/4025 , A61K31/453 , A61K31/496 , A61K31/501 , A61K45/06 , A61K47/6803 , A61K47/6869 , A61K47/6889 , C07D309/10 , C07D309/14 , C07D405/12 , C07D405/14 , C07D493/10 , C07D493/20
Abstract: The present invention is directed to novel cytotoxic spliceostatin analogs and derivatives, to antibody drug conjugates thereof, and to methods for using the same to treat medical conditions including cancer.
Abstract translation: 本发明涉及新颖的细胞毒素剪接抑制物类似物及其衍生物，其抗体药物偶联物及其用于治疗包括癌症在内的医学病症的方法。
-
公开(公告)号：US20190269791A1
公开(公告)日：2019-09-05
申请号：US16342275
申请日：2017-10-03
Applicant: Pfizer Inc.
Inventor： Andrea Therese HOOPER , Kimberly Ann MARQUETTE , Chakrapani SUBRAMANYAM , Hans-Peter GERBER , Chad Michael MAY
Abstract: The present invention provides antibodies and antibody-drug conjugates that bind to the extra domain B splice variant of fibronectin 1 and methods for preparing and using the same.
-
公开(公告)号：US20150307551A1
公开(公告)日：2015-10-29
申请号：US14793942
申请日：2015-07-08
Applicant: PFIZER INC.
Inventor： Matthew David DOROSKI , Andreas MADERNA , Christopher John O'DONNELL , Chakrapani SUBRAMANYAM , Beth VETELINO , Russell George DUSHIN , Pavel STROP , Edmund Idris GRAZIANI
IPC: C07K7/06
CPC classification number: C07K7/06 , A61K38/06 , A61K38/07 , A61K38/08 , A61K47/6803 , A61K47/6811 , A61K47/6851 , A61K47/6855 , A61K47/6863 , A61K47/6889 , C07K5/0205 , C07K5/0808 , C07K7/02 , C07K16/00 , C07K2319/30
Abstract: The present invention is directed to cytotoxic pentapeptides, to antibody drug conjugates thereof, and to methods for using the same to treat cancer.
Abstract translation: 本发明涉及细胞毒性五肽，其抗体药物偶联物及其用于治疗癌症的方法。
-
-
-
-
-
-
-
-
-
Search Results
16
records
(took 0.027 seconds)
